{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=20", "query": { "condition": "Oral Cavity", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 6517, "total_pages": 652, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T22:43:49.052Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01232595", "title": "Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate Clostridium Difficile Infection" ], "interventions": [ { "name": "LFF571", "type": "DRUG" }, { "name": "Vancomycin (POC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 109, "start_date": "2010-10", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 14, "location_summary": "Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more", "locations": [ { "city": "Palm Desert", "state": "California" }, { "city": "Bristol", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232595" }, { "nct_id": "NCT03152188", "title": "Oral Fecal Transplant in Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Encephalopathy", "Cirrhosis, Liver" ], "interventions": [ { "name": "FMT", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2017-06-12", "completion_date": "2018-11-12", "has_results": false, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 2, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152188" }, { "nct_id": "NCT05814627", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib Matching Placebo", "type": "DRUG" }, { "name": "Adalimumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2023-06-15", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 85, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814627" }, { "nct_id": "NCT00786669", "title": "A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cefixime", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 13, "start_date": "2008-10", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2021-02-10", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00786669" }, { "nct_id": "NCT00478556", "title": "Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Omnipaque", "type": "DRUG" }, { "name": "Gastroview", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 300, "start_date": "2007-08", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478556" }, { "nct_id": "NCT00574366", "title": "Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2005-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2016-05-10", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574366" }, { "nct_id": "NCT00161694", "title": "Use of Sucrose to Relieve Pain During Eye Exams in Infants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Apnea of Prematurity", "Retinopathy of Prematurity", "Pain" ], "interventions": [ { "name": "sucrose solution", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Weeks", "maximum_age": null, "sex": "ALL", "summary": "5 Weeks and older" }, "enrollment_count": 300, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-06-04", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161694" }, { "nct_id": "NCT00462605", "title": "MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ringed Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-07-18", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462605" }, { "nct_id": "NCT03715153", "title": "Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Autism Spectrum Disorder (ASD)" ], "interventions": [ { "name": "BUMETANIDE (S95008) for week 0 - 26", "type": "DRUG" }, { "name": "PLACEBO for week 0 - 26", "type": "DRUG" }, { "name": "Open-Label BUMETANIDE (S95008) for weeks 26 - 52", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Years to 6 Years" }, "enrollment_count": 211, "start_date": "2018-10-04", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 1, "location_summary": "Staten Island, New York", "locations": [ { "city": "Staten Island", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03715153" }, { "nct_id": "NCT04247542", "title": "ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "Ibezapolstat", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acurx Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 53, "start_date": "2020-03-06", "completion_date": "2023-11-15", "has_results": true, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-24T22:43:49.052Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • Apple Valley, California • Camarillo, California + 21 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" }, { "city": "Camarillo", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04247542" } ] }